TransCode Therapeutics Updates Preferred Stock Ownership LimitsTip Ranks·Jul 17 at 04:33 PMRNAZ-8.09%
TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq reviewPUBT·Jul 2 at 03:07 PMRNAZ-8.09%
RNAZ: Meeting adjourned to July 20, 2026, pending Nasdaq listing review completionQuartr·Jul 2 at 09:50 AMRNAZ-8.09%
Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watchrttnews·Jul 1 at 10:22 PMCANF-1.25%ELTX0.00%
Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focusrttnews·Jun 30 at 09:45 PMTRAX+18.33%SSII+13.96%
TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platformsPUBT·Jun 18 at 10:49 AMRNAZ-8.09%
Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watchrttnews·Jun 10 at 10:09 PMSI+2.69%RNAZ-8.09%
TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock NewsStockTitan·Jun 7 at 11:05 PMRNAZ-8.09%
TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update showing safety, tolerability, and disease stabilization with its lead candidate TTX-MC138.benzinga_article·Jun 3 at 11:57 AMRNAZ-8.09%
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Studybenzinga_article·Jun 3 at 06:41 AMRNAZ-8.09%
